MAA
ZVRA icon

Mraz Amerine & Associates’s Zevra Therapeutics ZVRA Stock Holding History

Mraz Amerine & Associates’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-890
Closed -$25K – 165
2018
Q4 		$25K Hold
890
– – 0.01% 151
2018
Q3 		$68K Hold
890
– – 0.02% 159
2018
Q2 		$93K Buy
+890
New +$86.9K 0.03% 160

Other funds holding ZVRA

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Mraz Amerine & Associates's ZVRA Position: Q1 2019 in Review

Mraz Amerine & Associates sold out of Zevra Therapeutics (ZVRA) in Q1 2019, closing a stake of 890 shares — an estimated $25K sold.

Mraz Amerine & Associates first reported a position in ZVRA in Q2 2018 and held it in 3 quarters. The position peaked at $93K in Q2 2018. 38 funds tracked by Wall St. Rank hold ZVRA as of Q1 2019.

  • Mraz Amerine & Associates reported no remaining Zevra Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Mraz Amerine & Associates sold 890 Zevra Therapeutics shares in Q1 2019, an estimated $25K.
  • Mraz Amerine & Associates first reported a position in Zevra Therapeutics in Q2 2018 and held it in 3 quarters.
  • Mraz Amerine & Associates's Zevra Therapeutics position peaked at $93K in Q2 2018.
  • 38 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2019.

Based on Mraz Amerine & Associates's 13F filing for Q1 2019, filed 8 May 2019.